LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Начало・Списък с акции・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

19.71 -1.55

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.68

Максимум

20.36

Ключови измерители
By Trading Economics
Приходи	258M 216M
Продажби	280M 459M
P/E Средно за сектора	52.778 105.69
EPS	1.67
Марж на печалбата	47.04
Служители	705
EBITDA	258M 228M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+65.18% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-1.4B 2.4B
Предишно отваряне	21.26
Предишно затваряне	19.71

Настроения в новините

By Acuity

56%

44%

307 / 374 Класиране в Healthcare

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.11.2025 г., 21:34 ч. UTC

Печалби

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13.11.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13.11.2025 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13.11.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13.11.2025 г., 23:24 ч. UTC

Печалби

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13.11.2025 г., 23:24 ч. UTC

Печалби

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13.11.2025 г., 23:23 ч. UTC

Печалби

JBS NV 3Q EPS 52c >JBS

13.11.2025 г., 23:23 ч. UTC

Печалби

JBS NV 3Q Sales $22.6B >JBS

13.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13.11.2025 г., 22:02 ч. UTC

Печалби

Nu Holdings 3Q Net $783M >NU

13.11.2025 г., 22:01 ч. UTC

Печалби

Nu Holdings 3Q Rev $4.2B >NU

13.11.2025 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13.11.2025 г., 21:50 ч. UTC

Печалби

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13.11.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13.11.2025 г., 21:41 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13.11.2025 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13.11.2025 г., 21:33 ч. UTC

Пазарно говорене

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13.11.2025 г., 21:33 ч. UTC

Печалби

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13.11.2025 г., 21:31 ч. UTC

Печалби

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13.11.2025 г., 21:25 ч. UTC

Печалби

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13.11.2025 г., 21:25 ч. UTC

Печалби

Figure Tech Solutions 3Q EPS 34c >FIGR

13.11.2025 г., 21:23 ч. UTC

Печалби

Intchains Group 3Q Rev $1.3M >ICG

13.11.2025 г., 21:03 ч. UTC

Печалби

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13.11.2025 г., 21:02 ч. UTC

Печалби

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13.11.2025 г., 21:01 ч. UTC

Печалби

Applied Materials 4Q Rev $6.8B >AMAT

13.11.2025 г., 21:01 ч. UTC

Печалби

Applied Materials 4Q Gross Margin 48.0% >AMAT

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

65.18% нагоре

12-месечна прогноза

Среден 33.07 USD 65.18%

Висок 52 USD

Нисък 18 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

16 ratings

Купи

Задържане

Продай

Според 16 анализатори, дали борсови рейтинги на Apellis Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

307 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.